Discovery of Early Type 1 Diabetes Disease Biomarkers in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of detecting beta cell destruction and protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN,, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models).  This FOA will not accept applications proposing a clinical trial.


  • Letter of Intent Due Date(s): April 10, 2018
  • Application Due Date(s): May 10, 2018

RFA-DK-17-021 Expiration Date May11, 2018

Agency Website



Amount Description

Application budgets are limited to $500,000 Direct Costs per year . Budgets are expected to reflect the actual needs of the proposed project.

The maximum project period is 4 years.  

    Funding Type





    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    May 10, 2018